The archive · Space, Robots, Defence · Product decision · 2023–2026
Lila Sciences bets AI runs the whole scientific method: $550M raised, $1.3B valuation
Flagship Pioneering spinout building 'scientific superintelligence' and automated labs; $350M Series A closed, $550M total, ~$1.3B valuation (Aug 2026)
Lila Sciences
What the business is
A Cambridge, MA company building a 'scientific superintelligence' platform and AI Science Factories: automated robotic labs that generate hypotheses, design and run experiments, and learn from results across life sciences, chemistry, and materials.
Starting capital：$235M initial round expanded and closed at $350M Series A; $550M total raised; ~$1.3B valuation (Aug 2026)
How it started
Flagship Pioneering founded Lila Sciences in 2023, with Geoffrey von Maltzahn, a former Flagship partner, as co-founder and CEO. Flagship had already spun out Moderna, and Lila's premise was that the scientific method itself — not any single domain — is what AI can automate.
What happened
Lila demonstrated early proof: AI-generated novel antibodies, carbon-capturing materials, and water-splitting catalysts that outperform the precious metals industry relies on — a third of which its Caltech-trained team initially dismissed, and which Fortune reported are now the highest-performing catalysts on record. Its first round grew from $235M to a $350M Series A closed in mid-2026 with NVentures (NVIDIA), Analog Devices, and others; total raised hit $550M at about a $1.3B valuation. It signed a 235,500 sq ft facility lease in Cambridge and began welcoming its first cohort of customers.
How it ended up
Scaling: $550M raised at ~$1.3B valuation, CNBC Disruptor 50 #25, first commercial customers in onboarding, and AI-designed water-splitting catalysts reported as the highest-performing on record.
Background
Lila Sciences is a Cambridge, Massachusetts company founded in 2023 by Flagship Pioneering, the incubator behind Moderna. Its bet is that the scientific method itself — pose a question, gather context, observe, reason, act — can be automated end-to-end by AI, which it calls 'scientific superintelligence.'
To make that real, Lila built AI Science Factories: automated robotic labs that run experiments continuously under the direction of its AI models. Proof of concept came fast: AI-generated novel antibodies, new carbon-capturing materials, and water-splitting catalysts that outperform the precious metals industry currently relies on. Geoffrey von Maltzahn told Fortune that a third of those catalyst suggestions made no sense to his Caltech-trained team at first, and are now the highest-performing catalysts on record.
Investors matched the ambition. Lila's first round grew from $235 million to a $350 million Series A, bringing total funding to $550 million and a valuation around $1.3 billion. New investors included NVentures (NVIDIA), Analog Devices, and IQT. In mid-2026 the company signed a lease on a 235,500 sq ft facility in Cambridge and began onboarding its first cohort of commercial customers.
Public attention followed the money: CNBC ranked Lila #25 on its 2026 Disruptor 50 list, and Exploding Topics data cited by Foundra in July 2026 showed 2,400% search-volume growth, making it one of the fastest-rising startup names of the month.
What has to be true
- The scientific method is the same loop in every field, so automating it once creates a platform that spans drugs, materials, and energy instead of a single product.
- Flagship's incubation gave Lila the capital and runway to build AI models and physical labs together, which pure-software startups cannot.
- Demonstrated wins in multiple domains — antibodies, carbon capture, catalysts — turned a philosophical bet into evidence investors could price.
- The $1.3B valuation while still onboarding its first customers shows the market priced the platform, not the revenue.
- A 2,400% search-growth month indicates the bet itself became the story people were looking up.
What can be applied
Automate the loop, not the product: Lila owns hypothesis, experiment, and learning across domains, so a breakthrough in one field becomes software IP that compounds into the next.
Aftermath
As of Aug 18, 2026, Lila had closed its Series A at $350 million for $550 million total, a valuation around $1.3 billion, a 235,500 sq ft Cambridge facility lease, and its first cohort of commercial customers in onboarding. Von Maltzahn was publicly arguing that agentic AI and the scientific method are structurally the same loop, and that the 'Claude Code moment' — when AI permanently changes how science is done — is imminent.
Sources
- Lila Sciences Named #25 on the 2026 CNBC Disruptor 50 List
- Lila Sciences' swollen first round, and other biofinancings
- AI drug discovery leaders warn U.S. health funding cuts risk falling behind global rivals
spotted an error? The archive wants to know.
Your turn
You just read one. Describe what you are building, and see who is betting on the same thing.
Free account · 3 free questions · no card